CSL Ltd. unit CSL Behring said Health Canada approved Afstyla for the treatment of hemophilia A.

Afstyla is a novel long-lasting recombinant factor VIII single-chain therapy for adults and children with the congenital bleeding disorder. The approval is based on the results of the Affinity clinical development program.

Afstyla is approved for use in the U.S. and Canada, and is being reviewed by regulators in global markets including the EU, Switzerland and Australia.